Transient Ischemic Attack.

TL;DR: This review summarizes the pro-angiogenic activity and the mechanism of TCM formulas, extracts, and compounds and delivers an in-depth understanding of the relationship between TCM and pro-ANGiogenesis and will provide new ideas for clinical practice.

TL;DR: In this article , a multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding five questions for adult ED patients with acute dizziness of less than 2 weeks' duration.

TL;DR: In this article , the authors focus on the correct clinical diagnosis, risk assessment, and management decisions of patients with suspected transient ischemic attack and discuss strategies for secondary prevention of future cerebrovascular events using maximal medical therapy and patient education.

TL;DR: In this article , the authors used multivariable generalised equation models for factors associated with poor functional outcome at 5 years and multiivariable cause-specific Cox hazard regression models in case of stroke recurrence.

TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.

TL;DR: These guidelines detail prehospital care, urgent and emergency evaluation and treatment with intravenous and intra-arterial therapies, and in-hospital management, including secondary prevention measures that are appropriately instituted within the first 2 weeks.

TL;DR: In this paper, the authors provided evidence-based recommendations for the prevention of future stroke among survivors of ischemic stroke or transient ischemi-chemic attack, including the control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke.

TL;DR: In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.